OTCM
BLFE
Market cap1kUSD
Jul 09, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Biolife Sciences Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioLife Sciences Corp. specializes in the creation, licensing, and distribution of both antibacterial solutions and advanced non-contact human temperature screening technologies. Its diverse product portfolio includes sanitizing wipes, ultraviolet (UV) sterilization equipment, professional electrostatic disinfection services, specialized anti-microbial fabrics, and innovative touch-free vending or marketplace systems. The company, which was established in 2018, operates from its base in Mississauga, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||